Literature DB >> 2278880

Lovastatin blocks N-ras oncogene-induced neuronal differentiation.

C E Mendola1, J M Backer.   

Abstract

ras p21 must be posttranslationally processed in order to be localized to the inner plasma membrane. The first obligatory processing step is the farnesylation of ras p21. Lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, may prevent the farnesylation of de novo synthesized ras p21. We demonstrate that N-ras oncogene-induced neuronal differentiation of UR61J rat pheochromocytoma cells is blocked by lovastatin. Our data show that this effect is due to the inhibition of ras p21 farnesylation. The results suggest that ras oncogene-induced phenotype in mammalian cells may be eliminated by preventing the proper processing of ras p21.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278880

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.

Authors:  Hsiao-Fang Wang; Yu-Tzu Shih; Chiung-Ya Chen; Hsu-Wen Chao; Ming-Jen Lee; Yi-Ping Hsueh
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

2.  Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.

Authors:  Jonathan W Wojtkowiak; Farid Fouad; Daniel T LaLonde; Miriam D Kleinman; Richard A Gibbs; John J Reiners; Richard F Borch; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2008-03-26       Impact factor: 4.030

3.  Lovastatin inhibits proliferation of rat mesangial cells.

Authors:  M P O'Donnell; B L Kasiske; Y Kim; D Atluru; W F Keane
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

4.  L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.

Authors:  Michael Feyder; Alessandra Bonito-Oliva; Gilberto Fisone
Journal:  Front Behav Neurosci       Date:  2011-10-24       Impact factor: 3.558

Review 5.  From neurodevelopment to neurodegeneration: the interaction of neurofibromin and valosin-containing protein/p97 in regulation of dendritic spine formation.

Authors:  Yi-Ping Hsueh
Journal:  J Biomed Sci       Date:  2012-03-26       Impact factor: 8.410

6.  Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model.

Authors:  Melania Muscas; Susana R Louros; Emily K Osterweil
Journal:  eNeuro       Date:  2019-06-12

7.  Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders.

Authors:  Myrthe J Ottenhoff; Lianne C Krab; Ype Elgersma
Journal:  eNeuro       Date:  2020-03-06

8.  Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.

Authors:  Emily K Osterweil; Shih-Chieh Chuang; Alexander A Chubykin; Michael Sidorov; Riccardo Bianchi; Robert K S Wong; Mark F Bear
Journal:  Neuron       Date:  2013-01-23       Impact factor: 17.173

9.  Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).

Authors:  S Kawata; T Nagase; E Yamasaki; H Ishiguro; Y Matsuzawa
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders.

Authors:  Melania Muscas; Sang S Seo; Susana R Louros; Emily K Osterweil
Journal:  eNeuro       Date:  2020-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.